Biocorrx (BICX) News Today $0.45 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsSEC FilingsShort InterestBuy This Stock BICX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)August 25, 2025 | globenewswire.comBioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) SalesAugust 14, 2025 | finance.yahoo.comBioCorRx Inc. (BICX) Latest Press Releases & Corporate News - Yahoo FinanceJune 1, 2025 | finance.yahoo.comBioCorRx Reports Business Update for the First Quarter of 2025May 20, 2025 | finance.yahoo.comBioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLCMarch 10, 2025 | finance.yahoo.comLa Rosa Holdings Corp. secures new financing, reshuffles leadershipOctober 6, 2024 | investing.comBioCorRx Inc: BioCorRx Reports Business Update for the Second Quarter of 2024August 16, 2024 | finanznachrichten.deBioCorRx Reports Business Update for the Second Quarter of 2024August 15, 2024 | globenewswire.comBioCorRx Reports Business Update for the First Quarter of 2024May 16, 2024 | finance.yahoo.comBioCorRx Inc. (BICX)April 18, 2024 | finance.yahoo.comBioCorRx receives new patent for novel compound to treat pain, depression, and schizophreniaApril 3, 2024 | seekingalpha.comBioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and SchizophreniaApril 3, 2024 | globenewswire.comBioCorRx Reports Business Update for 2023April 2, 2024 | globenewswire.comHow to Win a Business Grant: 4 Entrepreneurs Share Their TipsFebruary 29, 2024 | msn.comBioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUDFebruary 28, 2024 | globenewswire.comBIOCORRX INC NEW by BioCorRx Inc. Stock (OTC:BICX), Quotes and News SummaryFebruary 22, 2024 | benzinga.comBioCorRx Inc. (BICX) stock price, news, quote & history – Yahoo FinanceFebruary 13, 2024 | nz.finance.yahoo.comBioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of DirectorsFebruary 8, 2024 | finance.yahoo.comCollective Audience And 3 Other Stocks Under $1 Insiders Are BuyingJanuary 18, 2024 | msn.comBioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as PresidentJanuary 9, 2024 | finance.yahoo.comTAYNX Transamerica High Yield ESG-Class R4January 4, 2024 | seekingalpha.comCheng Fwa Industrial Ltd (5426)January 3, 2024 | investing.comBioCorRx Inc: BioCorRx Reports Business Update for the Third Quarter of 2023November 16, 2023 | finanznachrichten.deBioCorRx Reports Business Update for the Third Quarter of 2023November 14, 2023 | finance.yahoo.comBioCorRx President Awarded $14K Worth of Stock OptionsOctober 3, 2023 | benzinga.comBioCorRx Inc: BioCorRx Reports Business Update for the Second Quarter of 2023August 21, 2023 | finanznachrichten.deBioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use DisorderAugust 15, 2023 | finance.yahoo.comBioCorRx Reports Business Update for the Second Quarter of 2023August 14, 2023 | finance.yahoo.comTokai Holdings Corp (3167)July 29, 2023 | investing.comFukui Bank Ltd (8362)July 29, 2023 | investing.comNissha Printing Co Ltd (7915)July 28, 2023 | investing.comDSC Investment Inc (241520)July 18, 2023 | investing.comBioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use DisorderJuly 18, 2023 | finance.yahoo.comBioCorRx Inc: BioCorRx Provides Business Update for the First Quarter of 2023May 16, 2023 | finanznachrichten.deBioCorRx Provides Business Update for the First Quarter of 2023May 16, 2023 | finance.yahoo.comBioCorRx Provides Business Update for 2022April 3, 2023 | finance.yahoo.comBioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator MeetingMarch 7, 2023 | finance.yahoo.comBioCorRx to Present at Sequire Biotechnology Conference on February 2ndJanuary 27, 2023 | finance.yahoo.comBioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use DisorderJanuary 19, 2023 | finance.yahoo.comBioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United StatesDecember 7, 2022 | finance.yahoo.comBioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.November 22, 2022 | finance.yahoo.comBioCorRx Inc: BioCorRx Provides Business Update for the Third Quarter of 2022November 15, 2022 | finanznachrichten.deBioCorRx Provides Business Update for the Third Quarter of 2022November 15, 2022 | finance.yahoo.comBioCorRx to Present at the LD Micro Main Event XV on October 25thOctober 24, 2022 | finance.yahoo.comBioCorRx to Participate at the LD Micro Main Event XVOctober 20, 2022 | finance.yahoo.comBioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use DisorderOctober 13, 2022 | finance.yahoo.com2B3D Shares Addiction Treatment Deliverables from BioCorRx for Phase I of Mental Health Metaverse Platform BetaSeptember 29, 2022 | nz.finance.yahoo.comBICX: Pivotal trial underwaySeptember 16, 2022 | finance.yahoo.comBioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 6, 2022 | apnews.comABICX.PK - Biocorrx Inc | Stock Price & Latest News | ReutersSeptember 4, 2022 | reuters.com Get Biocorrx News Delivered to You Automatically Sign up to receive the latest news and ratings for BICX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BICX Media Mentions By Week BICX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BICX News Sentiment▼0.000.92▲Average Medical News Sentiment BICX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BICX Articles This Week▼00▲BICX Articles Average Week Get the Latest News and Ratings for BICX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Biocorrx and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CCM News Today MGRX News Today MRAI News Today PCHM News Today AMS News Today PFHO News Today BRTX News Today TNTY News Today BGLC News Today SSY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BICX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biocorrx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biocorrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
